Nivolumab Appears Safe, Effective in Wild-Type, Mutant BRAF Melanoma
the Cancer Therapy Advisor take:
Nivolumab has similar efficacy and safety outcomes in patients with wild-type or mutant BRAF metastatic melanoma, regardless of prior treatment with a BRAF inhibitor or ipilimumab, a recent study published in JAMA Oncology.
For the study, researchers conducted a pooled analysis from four clinical trials of nivolumab that included 440 adult patients with unresectable stage III or stage IV melanoma. All patients had been tested for BRAF mutational status and results showed that 334 were BRAF wild-type and 106 were BRAF V600 mutation-positive. The majority of patients received nivolumab 3mg/kg intravenously over 60 minutes every 2 weeks until disease progression, unacceptable toxicity, withdrawal, or end of study.
Results showed that the objective response rates were 34.6% (95% CI: 28.3-41.3) for the 217 evaluable patients with wild-type BRAF status and 29.7% (95% CI: 19.7-41.5) for the 74 evaluable patients with mutant BRAF status. Researchers found that objective response rates were not impacted by prior therapy with a BRAF inhibitor, ipilimumab, or PD-L1 tumor status.
In regard to safety, treatment-related adverse events of any grade occurred in 68.3% in the wild-type BRAF group compared with 58.5% in the mutant BRAF group.
Nivolumab has similar efficacy and safety outcomes in patients with wild-type or mutant BRAF metastatic melanoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Alcohol Consumption and Cancer
- Pancreatitis and the Risk of Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
- Depressed Patients With Head and Neck Cancer May Have Higher Mortality Rates
- MSK1 Levels Associated With Relapse, Metastasis in ER-positive Breast Cancer
- In the Clinic: Managing Malignant Pleural Effusions
- Does Depression Increase the Risk for Mortality Among Patients With Cancer?
- Nivolumab With Ipilimumab Promising for Pretreated Metastatic Sarcoma